The US drug regulatory authority, the Food and Drug Administration (FDA) is often thought to demand higher standards of consumer protection from drug manufacturers than its British counterparts, the Medicines Control Agency (MCA) and the Committee on the Safety of Medicines (CSM). Yet since 1991 the MCA has banned one of the most prescribed tranquillisers, Halcion, while it remains approved by the FDA and on the market in the United States. This article attempts to explain the Halcion anomaly and questions explanations proposed by previous sociological research in the field. Broad societal influences, such as the role of the mass media, the increasing threat of litigation regarding drug injury and deregulatory politics are considered to be unlikely explanations. Rather, microsociological processes concerning the internal organisation of the drug regulatory authorities and the interaction between that organisation and technical analyses of safety data are found to be the key explanatory factors.
Abraham, J.1993. `Scientific Standards and Institutional Interests: Carcinogenic Risk Assessment of Benoxaprofen in the UK and the US'. Social Studies of Science23: 387-444.
2.
Abraham, J.1994. `Negotiation and Accommodation in Expert Medical Risk Assessment and Regulation'. Policy Sciences27:53-76.
3.
Abraham, J. 1995. Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation. London/New York: UCL Press/St Martin's Press.
4.
Abraham, J. and Millstone, E.1989. `Food Additive Controls: Some International Comparisons'Food Policy14:43-58.
5.
Anello, C. 1988. 7/10/88 FDA memo to Dr Leber re `Halcion'.
6.
Brickman, R., Jasanoff, S. and Ilgen, T. 1985. Controlling Chemicals: The Politics of Regulation in Europe and the United States. Ithaca, NY. Cornell University Press.
7.
Bruzewski, K.J. 1989. 16/1/89 Upjohn internal memo of meeting with FDA, re `Halcion: Medical Event Reports'.
8.
Collier, J. 1989. The Health Conspiracy. London: Century.
9.
Crossen, S.E. 1994. Tainted Truth: The Manipulation of Fact in America. New York: Simon & Schuster.
10.
Day, M.1996. US Drug Safety Regime “Flawed” '. New Scientist, 9 November:10.
11.
Ehrlich, C.1988a. `Halcion Nightmare: The Frightening Truth about America's Favourite Sleeping Pill'. California, September:60-67, 119.
12.
Ehrlich, C.1988b `Halcion:Prescription for Trouble'California, October:74-77.
13.
Gabe, J. and Bury, M.1996. Halcion Nights: A Sociological Account of a Medical Controversy'. Sociology30:447-469.
14.
Gillespie, B., Eva, P. and Johnston, R.1979. `Carcinogenic Risk Assessment in the United States and Great Britain: The Case of Aldrin/Dieldrin'. Social Studies of Science9:265-301.
15.
Irwin, A. 1987. Risk and the Control of Technology: Public Policies for Road Traffic Safety Britain and the United States. Manchester: Manchester University Press.
16.
Jasanoff, S. 1990. The Fifth Branch: Science Advisers as Policymakers. Cambridge, Mass: Harvard University Press.
17.
Kelman, S. 1981. Regulating America, Regulating Sweden: A Comparative Study of Occupational Safety and Health Policy. Cambridge: MIT Press.
18.
Kendall, H.W. 1991. The failure of Nuclear Power', pp.163-218 in M. Shubik (ed.), Risk, Organizations and Society. Boston, Mass: Kluwer.
19.
Leber, P. 1984. 8/5/84 FDA memo to T. Woo and T. Hayes re Woo's proposals for Halcion labelling.
20.
Leber, P. 1988. 1/4/88 FDA memo of telecon to Director of Drug Research and Review re `Planned Upjohn announcement to discontinue manufacture of 0.5mg dose of Halcion'.
21.
Leber, P. 1989. 11/9/89 FDA memo to member of PDAC re `interpreting post-marketing surveillance information on Halcion'.
22.
Leber, P. 1991. 24/12/91 FDA memo to Robert Temple, Director, Office of Drug Evaluation re `recommendation to approve Zoloft (sertraline).
23.
McCrea, B. and Markle, G.E.1984. The Estrogen Replacement Controversy in the US and the UK: Different Answers to the Same Question?'Social Studies of Science14:1-26.
24.
Mason, D.J. 1989. Executive Director, US Pharmaceutical Regulatory Affairs, Upjohn 1/1/89 Letter to Dr Paul Leber, Director of Neuropharmacological Drug Products, FDA, re `Halcion tablets'.
25.
Millstone, E. 1986. Food Additives: Taking the Lid Off What We Really Eat. Harmondsworth: Penguin Books.
26.
Millstone, E. and Abraham, J. 1988. Additives: A Guide for Everyone. Harmondsworth: Penguin Books.
27.
Nelkin, D. (ed.) 1992. Controversies: Politics of Technical Decisions, 3rd edn.Newbury Park, Calif.: Sage.
28.
PDAC 1989. Transcript of Psychopharmacological Drugs Advisory Committee meeting, 22 September, FDA Headquarters.
29.
PDAC 1992. Transcript of Psychopharmacological Drugs Advisory Committee meeting. 18 May, FDA Headquarters.
30.
Pearce, N. 1996. `Adverse Reactions, Social Responses; A Tale of Two Asthma Mortality Epidemics' pp.57-75 in P. Davis (ed.) Contested Ground. Oxford: Oxford University Press.
31.
Public Citizen 1992. Citizen petition to FDA, 22 July, Washington DC.
32.
Richards, E. 1991. Vitamin C and Cancer. Medicine or Politics?London: Macmillan.
33.
Royal Courts of Justice 1994a. Transcription of Day 54 of Case between the Upjohn Company and Upjohn Ltd and Professor Ian Oswald and between Dr Royston Frederick Drucker and Professor Oswald and between the Upjohn Company and Upjohn Ltd and the BBC and Tom Mangold before Mr Justice May, Beverley F. Nunnery, London.
34.
Royal Courts of Justice 1994b. Judgement between the Upjohn Company and Upjohn Ltd and Professor Ian Oswald and between Dr Royston Frederick Drucker and Professor Oswald and between the Upjohn Company and Upjohn Ltd and the BBC and Tom Mangold before Mr Justice May, Beverley F. Nunnery, London.
35.
Stallings, R.A.1990. Media Discourse and the Social Construction of Risk'Social Problems37:80-95.
36.
US Congress 1990. Are Scientific Misconduct and Conflicts of Interest Hazardous to our Health? 19th report by the Committee on Government Operations, Washington, DC.
37.
US Congress 1992. Council on Competitiveness and FDA Plans to Alter the Drug Approval Process at the FDA. Hearings before the Committee on Government Operations, Washington, DC.
38.
Vaughan, D.1989. `Regulating Risk: Implications of the Challenger Accident'. Law & Policy11:330-349.
39.
Vogel, D. 1986. National Styles of Regulation: Environmental Policy in Great Britain and the United States. Ithaca, NY. Cornell University Press.
40.
Whitley, R.D. 1982. `The Establishment and Structure of the Sciences as Reputational Organizations', pp. 313-358 in N. Eliaset al. (eds.), Scientific Establishments and Hierarchies. London: Reidel.
41.
Whitley, R.D. 1984. The Intellectual and Social Organization of the Sciences. Oxford: Clarendon Press.
42.
Woo, T. 1984. 20/3/84 FDA Medical Officer's Review (MOR), Halcion.
43.
Wynne, B. 1987. Risk Management and Hazardous Waste: Implementation and the Dialectics of Credibility. London: Springer-Verlag.
44.
Wynne, B. 1989. `Frameworks of Rationality in Risk Management', in J. Brown (ed.), Environmental Threats. London: Belhaven.
45.
Wysowski, D.K. and Barash, D.1991. `Adverse Behavioural Reactions Attributed to Triazolam in the FDA's Spontaneous Reporting System', Archives of Internal Medicine151:2003-2008.
